EVENTS · NAMS
PEERS
EARNINGS
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.
NewAmsterdam Pharma Receives European Commission Approval for Ubeslo and Evlarco